Portal de Periódicos da CAPES

Awareness of cognitive decline trajectories in asymptomatic individuals at risk for AD

2020; BioMed Central; Volume: 12; Issue: 1 Linguagem: Inglês

10.1186/s13195-020-00700-8

1758-9193

Federica Cacciamani, Luisa Sambati, Marion Houot, Marie‐Odile Habert, Bruno Dubois, Stéphane Epelbaum, Christelle Audrain, Alexandra Auffret, Hovagim Bakardjian, Filippo Baldacci, Bénédicte Batrancourt, Ismahane Benakki, Habib Benali, Hugo Bertin, A. Bertrand, Laurie Boukadida, Federica Cacciamani, V. Causse, Enrica Cavedo, S. Cherif Touil, P. A. Chiesa, Olivier Colliot, G. Dalla Barba, M. Depaulis, Angela Dos Santos, Bruno Dubois, M. Dubois, Stéphane Epelbaum, Bertrand Fontaine, Hélène Francisque, Geoffroy Gagliardi, Alexis Génin, R Genthon, Pauline Glasman, F. Gombert, Marie‐Odile Habert, Harald Hampel, H. Hewa, Marion Houot, Navichka Jungalee, Aurélie Kas, M. Kilani, Valentina La Corte, Florence Le Roy, Stéphane Lehéricy, Claire Letondor, Marcel Lévy, Simone Lista, Mark Lowrey, Jenny Ly, Ornella Makiese, I. Masetti, Alexandre Mendes, C. Metzinger, Agnès Michon, Fanny Mochel, Ruhollah Arab, Francis Nyasse, C Perrin, Frédéric J.A.M. Poirier, C. Poisson, Marie‐Claude Potier, Stéphie Ratovohery, Marie Revillon, Katrine Rojkova, Katia Santos-Andrade, Rachel Schindler, M. C. Servera, Laure Seux, Valérie Simon, Daniel Skovronsky, Mathilde Thiébaut, Olga Uspenskaya, M. Vlaincu,

Health, Environment, Cognitive Aging

Abstract Background Lack of awareness of cognitive decline (ACD) is common in late-stage Alzheimer’s disease (AD). Recent studies showed that ACD can also be reduced in the early stages. Methods We described different trends of evolution of ACD over 3 years in a cohort of memory-complainers and their association to amyloid burden and brain metabolism. We studied the impact of ACD at baseline on cognitive scores’ evolution and the association between longitudinal changes in ACD and in cognitive score. Results 76.8% of subjects constantly had an accurate ACD (reference class). 18.95% showed a steadily heightened ACD and were comparable to those with accurate ACD in terms of demographic characteristics and AD biomarkers. 4.25% constantly showed low ACD, had significantly higher amyloid burden than the reference class, and were mostly men. We found no overall effect of baseline ACD on cognitive scores’ evolution and no association between longitudinal changes in ACD and in cognitive scores. Conclusions ACD begins to decrease during the preclinical phase in a group of individuals, who are of great interest and need to be further characterized. Trial registration The present study was conducted as part of the INSIGHT-PreAD study. The identification number of INSIGHT-PreAD study (ID-RCB) is 2012-A01731-42.